gs-2872
mAbexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 8, 2021 (NCT04811040)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusANTAGONIST
Human immunodeficiency virus antagonist
- Envelope proteinINHIBITOR
Envelope protein inhibitor
V3 glycan
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297679 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07054931 | Phase 2 | Sep 5, 2025 | University of Oxford |
| NCT06071767 | Phase 1/Phase 2 (Phase 2) | Jan 2, 2024 | Gilead Sciences, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford, University of Pittsburgh |
| NCT05729568 | Phase 2 | May 15, 2023 | Gilead Sciences |
| NCT04811040 | Phase 1 | Apr 8, 2021 | Gilead Sciences |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 3 | 2 | 2 | 2021 |
| University of Oxford | Academic/Hospital | 2 | 1 | 1 | 2024 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2024 |
| University of Pittsburgh | Academic/Hospital | 1 | 0 | 1 | 2024 |
4 organizations
Page 1 / 1